Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302
Yosuke Kawashima(Sendai Kousei Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Taku Nakagawa(Saint John's Health Center), Akira Inoue(Tohoku University Hospital), Toshiyuki Harada(Hokkaido hospital), Akimasa Sekine(Kanagawa Cardiovascular and Respiratory Center), Kei Takamura(Obihiro Kosei General Hospital), Kazuhiro Usui(Hokkaido University Hospital), Kenya Kanazawa(Fukushima Medical University), Yuka Fujita, Tomoya Kuda(Sendai Kousei Hospital), Kana Watanabe(Miyagi Prefectural Hospital Organization), Naoto Morikawa(Tohoku University)
Cited by 4
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695